Free Trial

Zynex Q2 2024 Earnings Report

Zynex logo
$8.25 -0.15 (-1.79%)
(As of 12/20/2024 05:40 PM ET)

Zynex EPS Results

Actual EPS
$0.04
Consensus EPS
$0.08
Beat/Miss
Missed by -$0.04
One Year Ago EPS
$0.09

Zynex Revenue Results

Actual Revenue
$49.88 million
Expected Revenue
$51.99 million
Beat/Miss
Missed by -$2.11 million
YoY Revenue Growth
+11.00%

Zynex Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Your chance to get on the next “60-Second Trade” (Ad)

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

Just head over here!

Zynex Earnings Headlines

Zynex (ZYXI) Gets a Buy from RBC Capital
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
See More Zynex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zynex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zynex and other key companies, straight to your email.

About Zynex

Zynex (NASDAQ:ZYXI), together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

View Zynex Profile

More Earnings Resources from MarketBeat

Upcoming Earnings